Immunologic Factor
ramucirumab Audio
[ ra-myoo-sir-yoo-mab ]
Brand Names:
Cyramza
Effect:
Vascular Growth Decrease
May Treat:
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Neoplasms
More Information:
ChemID; DrugBank; DailyMed; DrugInfo; PDR
Definitions related to ramucirumab:
  • A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
  • A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.